Merck & Co., Inc. (mrk)
MRK Estimates
Public analyst price targets and consensus snapshot for Merck & Co., Inc.. Deeper estimate history and models are available in Vest Terminal.
| Last price | $148.08 |
| Analyst mean target | $153.65 |
| Analyst high target | $186.00 |
| Analyst low target | $105.00 |
| Upside vs mean target | 3.8% |
| Consensus recommendation | Buy |
| Number of analysts | 26 |
| Forward P/E | 15.53 |
Start Free — open MRK in Vest Terminal
Access live data, filings, ownership, and analysis for Merck & Co., Inc..
Merck & Co., Inc. FAQ
What does Merck & Co., Inc. (MRK) do?
Merck & Co., Inc. operates as a healthcare company worldwide. It offers human health pharmaceutical for various areas under the Keytruda, Keytruda Qlex, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, Capvaxive, RotaTeq, Pneumovax 23, Bridion, Prevymis, Dificid, Zerb…
What is MRK's P/E ratio?
Merck & Co., Inc. has a trailing P/E of 120.39× based on publicly available market data.
Does MRK pay a dividend?
Indicated dividend yield: 2.2%. Confirm ex-dates and payout history in Vest Terminal.
What sector is MRK in?
Merck & Co., Inc. is classified in Healthcare (Drug Manufacturers - General) on NYQ.
What is MRK's market capitalization?
Approximate market cap: $365.34B.
What are the main risks for MRK?
Key risks include elevated valuation, among factors on this page.
What are the strengths of MRK?
Potential positives include revenue growth of 5.1% year-over-year, gross margin of 75.9% supports competitive unit economics.
Where can I get analyst estimates for MRK?
Public analyst price targets and consensus for Merck & Co., Inc. are on the free /stocks/mrk/estimates page. Deeper estimate history and models are available in Vest Terminal.